The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the ... If untreated, it can result in electrolyte imbalances, dehydration, and increases ...

Examples include Addison’s disease, Cushing’s syndrome, and congenital adrenal hyperplasia. Symptoms of adrenal disorders ...

Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. For more information about the Phase 2 TouCAHn study in classic CAH, please visit ...